In gastric cancer, the HER2/CEP17 ratio is decisive; in cases with higher gene counts (≥6.0) and negative ratio (<2.0) the tumor should be considered as HER2-positive in accordance with the updated recommendation for breast cancer (Wolff et al. 2013). The gene discussed is ERBB2; the disease is breast carcinoma.